The European Medicines Agency’s CHMP is recommending that Avastin (bevacizumab) be given approval for use in combination with chemotherapy to treat women with recurrent, platinum-sensitive ovarian cancer. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
